Morgan Stanley’s ChemoCentryx, Inc. CCXI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-684,161
| Closed | -$35.3M | – | 8147 |
|
|
2022
Q3 | $35.3M | Sell |
684,161
-223,225
| -25% | -$9.23M | ﹤0.01% | 1603 |
|
|
2022
Q2 | $22.5M | Buy |
907,386
+484,877
| +115% | +$10.7M | ﹤0.01% | 2158 |
|
|
2022
Q1 | $10.6M | Buy |
422,509
+33,905
| +9% | +$953K | ﹤0.01% | 2848 |
|
|
2021
Q4 | $14.1M | Buy |
388,604
+222,465
| +134% | +$7.81M | ﹤0.01% | 2536 |
|
|
2021
Q3 | $2.84M | Sell |
166,139
-221,922
| -57% | -$3.46M | ﹤0.01% | 4280 |
|
|
2021
Q2 | $5.2M | Buy |
388,061
+35,607
| +10% | +$877K | ﹤0.01% | 3741 |
|
|
2021
Q1 | $18.1M | Buy |
352,454
+294,396
| +507% | +$17.7M | ﹤0.01% | 2017 |
|
|
2020
Q4 | $3.6M | Buy |
58,058
+26,655
| +85% | +$1.53M | ﹤0.01% | 3617 |
|
|
2020
Q3 | $1.72M | Sell |
31,403
-68,285
| -68% | -$3.68M | ﹤0.01% | 3791 |
|
|
2020
Q2 | $5.74M | Buy |
99,688
+66,615
| +201% | +$3.63M | ﹤0.01% | 2530 |
|
|
2020
Q1 | $1.33M | Sell |
33,073
-58,685
| -64% | -$2.49M | ﹤0.01% | 3726 |
|
|
2019
Q4 | $3.63M | Sell |
91,758
-58,142
| -39% | -$1.02M | ﹤0.01% | 3534 |
|
|
2019
Q3 | $1.02M | Buy |
149,900
+144,309
| +2,581% | +$1.08M | ﹤0.01% | 4289 |
|
|
2019
Q2 | $52K | Sell |
5,591
-12,713
| -69% | -$147K | ﹤0.01% | 5587 |
|
|
2019
Q1 | $254K | Sell |
18,304
-21,267
| -54% | -$243K | ﹤0.01% | 4940 |
|
|
2018
Q4 | $432K | Sell |
39,571
-9,174
| -19% | -$96.7K | ﹤0.01% | 4874 |
|
|
2018
Q3 | $615K | Sell |
48,745
-6,201
| -11% | -$74.7K | ﹤0.01% | 4877 |
|
|
2018
Q2 | $723K | Sell |
54,946
-38,257
| -41% | -$458K | ﹤0.01% | 4843 |
|
|
2018
Q1 | $1.27M | Sell |
93,203
-56,869
| -38% | -$587K | ﹤0.01% | 4383 |
|
|
2017
Q4 | $894K | Buy |
150,072
+58,323
| +64% | +$400K | ﹤0.01% | 4613 |
|
|
2017
Q3 | $681K | Sell |
91,749
-24,116
| -21% | -$200K | ﹤0.01% | 4687 |
|
|
2017
Q2 | $1.09M | Sell |
115,865
-7,306
| -6% | -$53.6K | ﹤0.01% | 4318 |
|
|
2017
Q1 | $896K | Buy |
123,171
+12,310
| +11% | +$88.6K | ﹤0.01% | 4462 |
|
|
2016
Q4 | $820K | Buy |
110,861
+95,074
| +602% | +$685K | ﹤0.01% | 4618 |
|
|
2016
Q3 | $95K | Sell |
15,787
-39,397
| -71% | -$186K | ﹤0.01% | 5328 |
|
|
2016
Q2 | $248K | Buy |
55,184
+46,407
| +529% | +$174K | ﹤0.01% | 4833 |
|
|
2016
Q1 | $22K | Sell |
8,777
-5,771
| -40% | -$21K | ﹤0.01% | 5896 |
|
|
2015
Q4 | $118K | Buy |
14,548
+1,527
| +12% | +$10.8K | ﹤0.01% | 5319 |
|
|
2015
Q3 | $78K | Sell |
13,021
-28,785
| -69% | -$208K | ﹤0.01% | 5543 |
|
|
2015
Q2 | $344K | Buy |
41,806
+15,914
| +61% | +$126K | ﹤0.01% | 4950 |
|
|
2015
Q1 | $196K | Buy |
25,892
+19,458
| +302% | +$152K | ﹤0.01% | 5217 |
|
|
2014
Q4 | $44K | Hold |
6,434
| – | – | ﹤0.01% | 5851 |
|
|
2014
Q3 | $29K | Sell |
6,434
-14,018
| -69% | -$74.1K | ﹤0.01% | 5897 |
|
|
2014
Q2 | $120K | Buy |
20,452
+1,081
| +6% | +$6.07K | ﹤0.01% | 5414 |
|
|
2014
Q1 | $128K | Sell |
19,371
-46,157
| -70% | -$321K | ﹤0.01% | 5336 |
|
|
2013
Q4 | $380K | Sell |
65,528
-81,115
| -55% | -$418K | ﹤0.01% | 4647 |
|
|
2013
Q3 | $816K | Buy |
146,643
+124,934
| +575% | +$1.35M | ﹤0.01% | 3962 |
|
|
2013
Q2 | $306K | Buy |
+21,709
| New | +$281K | ﹤0.01% | 4592 |
|
Other funds holding CCXI
Morgan Stanley's CCXI Position: Q4 2022 in Review
Morgan Stanley sold out of ChemoCentryx, Inc. (CCXI) in Q4 2022, closing a stake of 684,161 shares — an estimated $35.3M sold.
Morgan Stanley first reported a position in CCXI in Q2 2013 and held it in 38 quarters. The position peaked at $35.3M in Q3 2022. 1 fund tracked by Wall St. Rank holds CCXI as of Q4 2022.
- Morgan Stanley reported no remaining ChemoCentryx, Inc. position as of Q4 2022 after selling out during the quarter.
- Morgan Stanley sold 684,161 ChemoCentryx, Inc. shares in Q4 2022, an estimated $35.3M.
- Morgan Stanley first reported a position in ChemoCentryx, Inc. in Q2 2013 and held it in 38 quarters.
- Morgan Stanley's ChemoCentryx, Inc. position peaked at $35.3M in Q3 2022.
- 1 fund tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2022.
Based on Morgan Stanley's 13F filing for Q4 2022, filed 14 Feb 2023.